<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795183</url>
  </required_header>
  <id_info>
    <org_study_id>AMISUL06155</org_study_id>
    <secondary_id>U1111-1131-0692</secondary_id>
    <nct_id>NCT01795183</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia</brief_title>
  <acronym>ESCAPE</acronym>
  <official_title>The Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia - A Prospective Open-Label Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the effectiveness of amisulpride in Chinese patients with schizophrenia

      Secondary Objective:

      To evaluate the overall safety of amisulpride in Chinese patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration by subject will include a 8-week treatment period with 3 follow-up visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective percentage (PANSS score reduced rate≥50%)</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early response rate (PANSS score reduced rate: at least 20%)</measure>
    <time_frame>week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)-total score improvement</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale- Improvement (CGI-I)</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">316</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMISULPRIDE</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Amisulpride</arm_group_label>
    <other_name>Solian</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Satisfying International Classification of Disease-10 (ICD) diagnostic criteria of
             schizophrenia;

          -  Positive and Negative Syndrome Scale (PANSS) total score ≥ 60

        Exclusion criteria:

          -  Refractory schizophrenia or Patients treated with sufficient clozapine for a minimum
             period of 6-8 weeks without improvement;

          -  Participation into another clinical trial within the last month;

          -  Patients previously or currently treated with amisulpride;

          -  Patients receiving clozapine within the past 1 month or treated with long-acting
             formulation of antipsychotic medication within the past 2 months;

          -  Patients receiving electric convulsive therapy or physical therapy within the past 1
             month;

          -  Patients with coexisting severe systemic diseases;

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

